Pioneer in evidence-based medicine releases tumor-associated biomarker to help
confirm diagnoses of prostate carcinoma
DEDHAM, Mass., Nov. 1 /PRNewswire/ -- Signet Laboratories, Inc., a pioneer
in evidence-based medicine (EviMed), today announced the availability of its
IVD P504s antibody, for the detection of prostate cancer.
P504s is useful in detecting prostate carcinoma in samples obtained from
prostatectomies, prostate needle biopsies, and transurethral prostate
resections. P504s shows strong cytoplasmic granular staining in prostate
carcinomas.
P504s positively stains prostatic adenocarcinoma cells, premalignant
lesions of the prostate, high-grade prostatic intraepithelial neoplasia (PIN)
and atypical adenomatous hyperplasia. The P504s protein is expressed in
malignant prostate tissues, and only very weakly, if at all in benign
prostatic tissue -- the staining for each case being easily distinguishable.
According to Angela Thomas, IHC Product Manager for Signet Laboratories,
"P504s is a highly sensitive and specific marker for prostate carcinoma with
demonstrated use in detecting and clearly marking malignant tissues and
atypical prostate biopsies. Signet is pleased to offer P504s to customers,
expanding our product portfolio, and our prostate antibody panel."
About Signet Laboratories, Inc.
Signet Laboratories, Inc. is a pioneering evidence-based medicine (EviMed)
company that is committed to developing and commercializing predictive
diagnostics and preventive drugs and therapies for critical disease states.
Evidence-based medicine is the treatment of diseases prior to their full
manifestation, with the goal of reducing their occurrence and preventing
disease progression by early identification of patients with increased risk
factors.
Drawing on long experience in developing diagnostic assays and antibodies
for disease detection and treatment, Signet's mission is to create novel
diagnostics and drugs for patients at risk for cancer, sepsis and renal
failure (SARF), neurodegenerative diseases including Alzheimer's, Parkinson's
and Huntington's, and prion diseases such as "Mad Cow" and vCJD.
In addition to diagnostics, drugs and therapies, Signet offers a complete
product line of over 800 manufactured antibodies, ELISA kits, detection
products and accessories in an FDA registered facility. Signet products are
available online, at http://www.signetlabs.com.
Contact Information
Ms. Terri Daly
Marketing Communications
Signet Laboratories, Inc.
180 Rustcraft Road
Dedham, MA 02026
Phone: 781.915.1404
Fax: 781.461.2456
tdaly@signetlabs.com
SOURCE Signet Laboratories, Inc.
 back to top
Related links:
http://www.signetlabs.com
CONTACT:
Ms. Terri Daly, Marketing Communications of
Signet Laboratories, Inc., +1-781-915-1404, tdaly@signetlabs.com
|
